Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind, Placebo-controlledTrial of Golimumab, a Fully Human Anti-TNFa MonoclonalAntibody, Administered Subcutaneously, in Subjects With ActiveRheumatoid Arthritis Despite Methotrexate Therapy
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of golimumab, alone or in combination with methotrexate (MTX), as compared to methotrexate alone in rheumatoid arthritis (RA) patients who have active rheumatoid arthritis despite treatment with MTX.


Options:
A: Arm Label: methotrexate + adalimumab; Type: EXPERIMENTAL; Interventions: Drug: Adalimumab | Arm Label: methotrexate + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): methotrexate + adalimumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): methotrexate + placebo
B: Arm Label: 1a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate | Arm Label: 1b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate, Drug: Placebo | Arm Label: 2a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate, Drug: Placebo | Arm Label: 2b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 1a, 1b, 2a | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1a, 1b, 2a, 2b | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1b, 2a
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1, 2, 3
D: Arm Label: Group 1: Placebo + Methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Placebo injection | Arm Label: Group 2: Golimumab 100 mg + Placebo; Type: EXPERIMENTAL; Interventions: Drug: Golimumab 100 mg, Drug: Placebo capsules | Arm Label: Group 3: Golimumab 50 mg + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Golimumab 50 mg, Drug: Methotrexate | Arm Label: Group 4: Golimumab 100 mg + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Golimumab 100 mg, Drug: Methotrexate | Intervention Type: DRUG; Name: Golimumab 100 mg; Assigned to Arm(s): Group 2: Golimumab 100 mg + Placebo, Group 4: Golimumab 100 mg + Methotrexate | Intervention Type: DRUG; Name: Golimumab 50 mg; Assigned to Arm(s): Group 3: Golimumab 50 mg + Methotrexate | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Group 1: Placebo + Methotrexate, Group 3: Golimumab 50 mg + Methotrexate, Group 4: Golimumab 100 mg + Methotrexate | Intervention Type: DRUG; Name: Placebo injection; Assigned to Arm(s): Group 1: Placebo + Methotrexate | Intervention Type: DRUG; Name: Placebo capsules; Assigned to Arm(s): Group 2: Golimumab 100 mg + Placebo

Answer: D